TREATMENT OF OCULAR DISEASE
Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.
1 - 20 . (canceled)
21 . A method for treating an ocular condition in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) binding agent, wherein the therapeutically-effective amount of the HPTPβ-ECD binding agent is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject, wherein the HPTPβ-ECD binding agent is a monoclonal antibody or an antigen-binding fragment thereof.
22 . The method of claim 21 , wherein the HPTPβ-ECD binding agent binds to an FN3 repeat in the HPTPβ-ECD.
23 . The method of claim 21 , wherein the HPTPβ-ECD binds to a first FN3 repeat in the HPTPβ-ECD.
24 . The method of claim 21 , wherein the HPTPβ-ECD binding agent inhibits HPTPβ.
25 . The method of claim 21 , wherein the HPTPβ-ECD binding agent binds to SEQ ID NO.: 4.
26 . The method of claim 21 , wherein the HPTPβ-ECD binding agent is administered in a composition, wherein the composition comprises a pharmaceutically-acceptable carrier.
27 . The method of claim 21 , wherein the monoclonal antibody or the antigen-binding fragment thereof is conjugated to a vehicle.
28 . The method of claim 27 , wherein the vehicle is polyethylene glycol.
29 . The method of claim 21 , wherein the HPTPβ-ECD binding agent is administered by intraocular injection.
30 . The method of claim 21 , wherein the HPTPβ-ECD binding agent is administered by subcutaneous injection.
31 . The method of claim 21 , wherein the HPTPβ-ECD binding agent is administered by intravenous injection.
32 . The method of claim 21 , wherein the subject is human.
33 . A composition comprising:
a) a therapeutically-effective amount of a multi-specific antibody; and
b) a carrier,
wherein the multi-specific antibody binds to a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) in a subject, and wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject.